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Abstract
Purpose Leflunomide (LEF) is a disease-modifying antirheu-
matic drug used for treating rheumatoid arthritis (RA) and the
actionofwhichmaybemodifiedbysexhormones.Theaimof
this study was to examine the association between CAG
repeat polymorphism in the androgen receptor (AR)g e n ea n d
the response to treatment with LEF in women with RA.
Methods We studied 114 women diagnosed with RA and
treated with LEF (20 mg daily). Follow-up was 12 months.
CAG repeat polymorphism was determined using polymer-
ase chain reaction (PCR) and subsequent fragment analysis
by capillary electrophoresis.
Results Analysis revealed no statistically significant asso-
ciations between CAG repeat polymorphism in the AR gene
and improvement of disease activity parameters: erythrocyte
sedimentation rate, serum C-reactive protein, patient’s
global assessment of disease activity on a visual analog
scale (VAS), disease activity score of 28 joints (DAS28),
and swollen and tender joint count.
Conclusion Our results suggest no correlation between
CAG repeat polymorphism in the AR gene and response
to treatment with LEF in women with RA.
Keywords (CAG)n repeat polymorphism.Androgen
receptor.Leflunomide.Rheumatoid arthritis
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
systemic disease that affects the joints and often leads to
severe disability. Disease-modifying antirheumatic drugs
(DMARDs), such as methotrexate, sulphasalazine, and
leflunomide (LEF), can retard joint destruction [1–3]. It
has been shown that LEF is effective and well tolerated in
the treatment of RA [4]. One mechanism of LEF action in
suppressing inflammation is based on its inhibition of
dihydroorotate dehydrogenase (DHODH), an enzyme re-
sponsible for de novo synthesis of pyrimidine nucleotides.
Moreover, polymorphism in the DHODH gene may be
associated with LEF treatment response and toxicity [5, 6].
Upon absorption, LEF is quickly metabolized to malononi-
trilamide (MNA or A77 1726) as the active therapeutic
agent. MNA selectively inhibits DHODH and, thus,
suppresses T-cell proliferation [7]. Via its effect on T cells,
LEF addresses several levels of the inflammatory cascade and
has antiproliferative, antiinflammatory, and antidestructive
abilities [8, 9]. The antiinflammatory effect is related to its
ability to inhibit osteoclastogenesis and production of metal-
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synovial cells and macrophages [10, 11]. This special mode
of action, together with its rapid onset of action, makes it a
promising drug for treating RA, in which preventing
irreversible structural damage is an important goal.
Previous studies indicated poorer response to treatment in
women than in men [12, 13]. Possible reasons for gender
differences in RA activity could be explained on the basis of
sex hormones and their receptors. Sex hormones, acting
through their intracellular receptors, play an important role in
regulating the immune/inflammatory response in RA [14].
The androgen receptor (AR) gene, present on the X
chromosome, contains a highly polymorphic CAG (gluta-
mine) repeat in the region encoding NH2-terminal trans-
activation domain, which normally varies between 9 and 37
repeats (approximately 10–30 in Caucasians) [15, 16]. CAG
length [(CAG)n] is inversely associated with the AR
transcriptional activity such that, having longer (CAG)n,i t
reduces AR transcriptional activity and subsequent intracel-
lular androgenic activity [16, 17]. Studies have shown that
the AR CAG polymorphism is clinically relevant. (CAG)n
longer than about 37 repeats is associated with pathologic
conditions related to reduced androgenicity, such as gyneco-
mastia and ineffective spermatogenesis [16]. Shorter AR
CAG repeats have been associated with hormone-related
cancer risk, such as prostate cancer [18].
In our previous study, we indicated that estrogen
receptor gene (ESR1) polymorphisms in women with RA
may be associated with response to treatment with LEF
[19]. The aim of the study presented here was to examine
the association between CAG repeat polymorphism in the
androgen receptor gene and response to therapy of women
with RA treated with LEF.
Materials and methods
Patients
The study was carried out on 114 women, mean age 54.1±
11.0 years, diagnosed with RA (disease duration 10.8±
7.0 years). Monotherapy of 20 mg/day LEF was used. RA
was diagnosed according to criteria of the American
College of Rheumatology (ACR). All patients underwent
a monthly evaluation for 1 year from initiation of treatment
with LEF. The assessed variables included the number of
swollen joints, number of tender joints, patient’s global
assessment of disease activity on a 10-cm visual analog
scale (VAS), erythrocyte sedimentation rate (ESR), serum
C-reactive protein (CRP), and disease activity score for 28
joints (DAS28) (including metacarpophalangeal joints,
proximal interphalangeal joints, wrists, and elbows) [20–
22]. Written informed consent was obtained from patients
according to the Declaration of Helsinki, and the Ethical
Committee approved the study design.
Genotyping
Genomic DNA was extracted from 200 μl of whole blood
samples with GeneMATRIX Quick Blood DNA Purifica-
tion Kit (EURx, Poland) and subsequently standarized to
20 ng/μl concentration. The DNA region containing CAG
repeats within the AR gene was amplified with a pair of
flanking primers: 5’-TCC AGA ATC TGT TCC AGA GCG
TGC-3’,5 ’-ACT GCG GCT GTG AAG GTT GCT GT-3’
[23]. Forward primer was fluorescently labeled with 6-
carboxyfluorescein (6-FAM). Amplification was carried out
in 15 μl volume using AmpliTaq Gold 360 Master Mix
(Applied Biosystems, USA), 0.2 μM of each primer, and 1
μl of genomic DNA, in 27-cycle polymerase chain reaction
(PCR) (primer annealing temperature 57°C). Length of the
amplification product was subsequently analyzed by capil-
lary electrophoresis: 1 μl of each sample was mixed with
12 μl of Hi-Di Formamide (Applied Biosystems)+0.5 μlo f
GeneScan 500 LIZ Size Standard and put into an ABI
PRISM 3130 Genetic Analyzer with an autosampler
module. Electrophoresis was run on 36-cm capillary arrays
filled with POP-4 polymer. Data were gathered with Data
Collection v.3.0 software and further analyzed with Gene-
Mapper ID-X 1.1 software. A number of CAG repeats
corresponding to the length of amplified DNA fragments
assessed by capillary electrophoresis was verified by
sequencing of randomly chosen homozygous samples using
the same primers as described above. PCR product was
initially purified using YM-100 centrifugal filters (Micro-
con, USA) and sent out for sequencing to a commercial
service (oligo.pl, Poland).
Statistical analysis
Distributions of disease activity parameters were signifi-
cantly different from normal (p<0.05, Shapiro-Wilk test) in
most cases. Therefore, we used nonparametric tests. The
Kruskal–Wallis test was followed by the Mann–Whitney
test to compare disease activity parameters and their
changes between genotype groups. Spearman rank correla-
tion coefficient (Rs) was calculated to measure correlations
between the number of CAG repeats and disease activity
parameters. P<0.05 was considered statistically signifi-
cant. We performed power calculation based on standard
deviation (SD) of DAS28 improvement (0.8) from our
previous study [19] to compare AR genotypes. It revealed
that the study reported here, with 114 patients, has
statistical power sufficient to detect with 80% probability
the differences of DAS28 improvement between genotype
groups equal to 0.6.
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The number of AR CAG repeats in the studied group
ranged from 11 to 34 (median 22). The frequency
distribution of AR genotypes was in Hardy–Weinberg
equilibrium (p=0.80). AR genotypes and alleles were
classified according to median. Alleles with <22 CAG
were classified as short (S) and those with ≥22 CAG as
long (L). The patients studied could thus be divided into
three groups: those with two short alleles (S-S, n=31), those
with two long alleles (L-L, n=31), and those with one short
and one long allele (S-L, n=52).
Table 1 presents the associations between disease activity
parametersandAR genotypes at onset and after 12 months of
treatment with LEF. As shown, there were no statistically
significant differences between genotype groups compared
with Kruskal–Wallis test. The improvement of disease
activity parameters during treatment with LEF in association
with AR genotypes is presented in Table 2. These associa-
tions were statistically nonsignificant.
We also analyzed the shorter and the longer allele
CAG repeats separately. Additionally, for each patient,
the mean number of repeats was calculated from the
formula (shorter allele CAG repeats + longer allele
CAG repeats)/2. With regard to disease activity param-
eters in patients stratified according to median CAG
repeat length of shorter AR allele (19), longer AR allele
(23), and their mean (21.5), there were statistically
significant associations with some baseline disease activ-
ity parameters (ESR, CRP, VAS); however, there were no
associations with the parameters after 12 months of
therapy with LEF or with changes in parameters during
therapy (Table 3).
We analyzed correlations between RA activity param-
eters and CAG repeat length of AR alleles at onset and
after 12 months of therapy. The only statistically signif-
icant associations were negative correlations between the
VAS and CAG repeats in longer allele (Rs=−0.25, p=0.006)
and mean of CAG repeats in shorter and longer alleles
(Rs=−0.22, p=0.02). Spearman rank correlation coeffi-
cients between changes of RA activity parameters during
treatment with LEF and CAG repeat length of AR alleles
are shown in Table 4. No significant correlations were
found.
Table 1 The association of disease activity parameters with androgen receptor (AR) genotypes at onset and after 12 months of treatment with
leflunomide
Parameters AR genotypes (mean±SD) P value
a P value
b
S-S S-L L-L S-S vs L-L S-S vs S-L+L-L S-S+S-L vs L-L
ESR (mm/h)
At onset 61.5±27.5 48.6±26.9 49.2±22.6 0.057 0.053 0.017 0.53
After 12 months 39.0±23.2 34.1±23.7 33.5±20.1 0.61 0.47 0.34 0.83
Number of swollen joints
At onset 8.55±2.67 7.69±3.12 8.71±4.51 0.24 0.56 0.16 0.76
After 12 months 1.04±1.68 1.19±1.62 0.83±1.19 0.54 0.99 0.57 0.59
Number of tender joints
At onset 10.39±3.33 10.02±3.32 10.00±4.82 0.35 0.18 0.32 0.18
After 12 months 2.65±2.08 2.33±2.27 2.65±2.71 0.71 0.71 0.49 0.93
VAS
At onset 8.12±1.21 7.44±1.41 7.28±1.61 0.068 0.037 0.025 0.19
After 12 months 2.25±1.41 2.39±1.57 2.47±2.10 0.95 0.88 0.79 0.99
DAS28
At onset 5.51±0.58 5.23±0.65 5.30±0.63 0.14 0.097 0.047 0.42
After 12 months 3.52±0.89 3.38±0.92 3.33±0.74 0.81 0.55 0.53 0.88
CRP (mg/L)
At onset 52.50±42.99 39.30±36.46 37.55±33.23 0.34 0.17 0.14 0.52
After 12 months 14.59±18.46 8.87±11.79 17.87±24.55 0.13 0.96 0.25 0.29
SD standard deviation, S short allele (<22 CAG repeats), L long allele (≥22 CAG repeats) , ESR erythrocyte sedimentation rate, VAS visual analog
scale (0–10), CRP C-reactive protein, DAS28 disease activity score of 28 joints
a Kruskal–Wallis test
b Mann-Whitney test
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This is the first study examining the association
between CAG repeat polymorphism in the AR gene and
response to therapy in women with RA treated with LEF.
Response to treatment was evaluated on the basis of
improvement of disease activity parameters, such as
DAS28, VAS, number of swollen and tender joints, ESR,
and CRP levels. The analysis found no statistically
significant associations. Previous studies have shown the
inverse correlation of CAG length with transcriptional
activity of the AR,w h i c hm a yb ea s s o c i a t e dw i t ha l t e r e d
response to androgens [16, 17]. Androgen serum concen-
trations were not measured in our patients, and their
associations with CAG length and response to therapy
could not be analyzed.
So far, the length of the CAG repeat polymorphism of
AR in RA has not been widely investigated. Studies
regarding this polymorphism suggest associations between
CAG repeat length and clinical features of RA but no
association with susceptibility to RA [24–26]. Only one
study examined the association between CAG polymorphism
of the AR gene and response to therapy in RA. Patients
harboring long CAG alleles with >23 repeats had an
increased risk of a worse response to DMARDs, but it was
not shown how many patients were treated with LEF [27].
The implication for our study was the observation that
sex hormones play an important role in RA pathogenesis
and that response to DMARDs is poorer in women than in
men [12–14]. Moreover, in our previous study, we
indicated better response to treatment in patients with
ESR1 rs9340799 AA and rs2234693 TT genotypes after
12 months of therapy with LEF [19]. Additionally, the
influence of sex hormones on LEF action has been
confirmed by in vitro studies. Cutolo et al. [28] studied
the combined effects of LEF, 17β-estradiol, and testoster-
one on inflammatory cytokine production by cultured
macrophages obtained from activated human monocytes.
The authors evaluated the levels of interleukin 6 (IL-6),
tumor necrosis factor alpha (TNF-α), and transforming
growth factor beta (TGF-β) in cell cultures. They showed
that LEF significantly down-regulated cytokine production.
Treatment with testosterone induced a significant decrease
in cytokine production in differentiated macrophages,
whereas 17β-estradiol increased cytokine expression. In-
terestingly, in a synergistic way, LEF in combination with
testosterone induced a further significant decrease in all
cytokines analyzed versus cells already treated with
testosterone alone. On the other hand, 17β-estradiol
inhibited the decrease of LEF-induced cytokine production
in differentiated macrophages. The authors conclude that
17β-estradiol seems to contrast, but testosterone seems to
synergize, LEF activity, and these results might support the
observations that a less effective therapeutic effect in
women with RA is due to the action of estrogens [28].
Montagna et al. [29] evaluated the proapoptotic activity of
LEF in combination with sex hormones on cultures of
human macrophages treated with LEF alone or in the
presence of 17β-estradiol or testosterone. The authors
showed that LEF significantly increased the expression of
Table 2 The improvement of disease activity parameters during treatment with leflunomide in association with AR genotypes
Parameters AR genotypes (mean ± SD) P value
a P value
b
S-S S-L L-L S-S vs L-L S-S vs S-L+L-L S-S+S-L vs L-L
ESR (mm/h) −23.2±32.3 −16.1±30.0 −18.0±23.6 0.67 0.49 0.37 0.72
(−36.0 to −10.4) (−26.3 to −6.0) (−28.1 to −7.8)
Number of swollen
joints
−7.88±2.97 −6.75±3.29 −8.30±4.92 0.20 0.77 0.19 0.57
(−9.08 to −6.68) (−7.86 to −5.64) (−10.43 to −6.18)
Number of tender
joints
−7.65±3.21 −7.64±3.53 −7.65±4.73 0.81 0.64 0.88 0.53
(−8.95 to −6.36) (−8.83 to −6.44) (−9.70 to −5.61)
VAS −5.79±1.86 −5.10±1.81 −4.87±2.50 0.12 0.091 0.044 0.26
(−6.54 to −5.04) (−5.71 to −4.48) (−5.95 to −3.79)
DAS28 −1.99±0.87 −1.90±0.76 −2.03±0.86 0.89 0.89 0.74 0.86
(−2.33 to −1.65) (−2.15 to −1.64) (−2.40 to −1.66)
CRP (mg/L) −33.12±40.18 −33.64±39.47 −19.53±24.14 0.43 0.42 0.93 0.22
(−49.71 to −16.54) (−46.99 to −20.28) (−30.23 to −8.83)
Mean±standard deviation (SD) (95% confidence interval for mean) for the differences of parameters measured after 12 months of therapy and
before therapy in each patient
S short allele (<22 CAG repeats), L long allele (≥22 CAG repeats), ESR erythrocyte sedimentation rate, VAS visual analog scale, DAS28 disease
activity score of 28 joints, CRP C-reactive protein
a Kruskal-Wallis test
b Mann-Whitney test
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CAG repeat length of shorter androgen receptor (AR) allele, longer AR allele, and their mean
Parameters CAG repeats in shorter allele CAG repeats in longer allele Mean of CAG repeats in shorter and longer
alleles
b
Mean values±SD Mean values±SD Mean values±SD
≤19 CAG >19 CAG p
a ≤23 CAG >23 CAG p
a ≤21.5 CAG >21.5 CAG p
a
ESR (mm/h)
At onset 53.5±27.3 51.4±25.8 0.71 57.2±27.7 47.2±24.2 0.044 56.3±28.4 48.8±24.1 0.17
After 12 months 39.1±25.5 32.7±19.8 0.36 34.8±20.6 36.3±25.0 0.90 35.5±21.4 35.5±23.7 0.96
Change −16.9±32.8 −20.3±26.2 0.69 −23.5±30.2 −12.6±26.6 0.099 −23.1±31.2 −14.8±26.6 0.23
Number of swollen joints
At onset 8.27±3.35 8.15±3.55 0.61 8.17±3.20 8.23±3.72 0.79 8.19±3.29 8.21±3.62 0.91
After 12 months 1.24±1.89 0.90±1.17 0.72 1.29±1.83 0.73±0.93 0.41 1.17±1.87 0.93±1.13 0.86
Change −7.59±3.57 −7.46±3.89 0.75 −7.23±3.37 −7.89±4.18 0.51 −7.54±3.47 −7.50±4.00 0.87
Number of tender joints
At onset 10.04±3.31 10.17±4.09 0.80 10.34±3.59 9.88±3.94 0.30 10.57±3.65 9.72±3.84 0.097
After 12 months 2.73±2.18 2.35±2.43 0.25 2.65±2.15 2.35±2.54 0.30 2.59±2.26 2.45±2.40 0.70
Change −7.73±3.63 −7.58±3.89 0.78 −7.56±3.45 −7.76±4.17 0.82 −7.95±3.56 −7.36±3.95 0.39
VAS
At the onset 7.60±1.28 7.57±1.57 1.00 7.99±1.30 7.17±1.48 0.0025 7.97±1.28 7.25±1.51 0.010
After 12 months 2.34±1.63 2.39±1.72 0.79 2.49±1.51 2.22±1.87 0.23 2.38±1.56 2.36±1.78 0.92
Change −5.36±1.94 −5.16±2.13 0.58 −5.45±1.77 −4.99±2.35 0.35 −5.57±1.76 −4.95±2.25 0.16
DAS28
At the onset 5.34±0.61 5.31±0.66 0.77 5.42±0.64 5.23±0.62 0.057 5.42±0.65 5.25±0.61 0.074
After 12 months 3.56±0.89 3.30±0.83 0.39 3.51±0.91 3.27±0.77 0.33 3.47±0.95 3.35±0.76 0.79
Change −1.89±0.83 −2.02±0.81 0.74 −1.91±0.80 −2.04±0.83 0.55 −1.98±0.82 −1.95±0.81 0.71
CRP (mg/L)
At the onset 43.50±41.16 41.59±35.20 0.66 50.85±43.06 33.67±29.12 0.049 50.44±44.95 35.44±28.65 0.23
After 12 months 15.00±18.36 11.42±17.96 0.38 13.33±16.70 12.53±19.95 0.47 12.90±16.47 13.05±19.71 0.70
Change −29.69±40.67 −29.78±33.22 0.30 −36.04±43.48 −21.91±23.26 0.48 −36.76±45.45 −23.22±24.05 0.74
SD standard deviation, ESR erythrocyte sedimentation rate, VAS visual analog scale, DAS28 disease activity score of 28 joints, CRP C-reactive
protein,
a Mann-Whitney test
b (shorter allele CAG repeats + longer allele CAG repeats)/2
Table 4 Spearman rank correla-
tion coefficients and their 95%
confidence intervals (CI) between
improvement of rheumatoid
arthritis disease activity
parameters during treatment with
leflunomide and CAG repeat
length of androgen receptor (AR)
alleles (shorter, longer, and mean)
No significant (p<0.05)
correlations were found
ESR erythrocyte sedimentation
rate, VAS visual analog scale,
DAS28 disease activity score of
28 joints, CRP C-reactive protein
a (shorter allele CAG repeats+
longer allele CAG repeats)/2
Parameters CAG repeats in
shorter allele
CAG repeats in
longer allele
Mean of CAG repeats in
shorter and longer alleles
a
ESR +0.06 +0.11 +0.09
(−0.16 – +0.28) (−0.11 – +0.32) (−0.13 – +0.30)
Number of swollen joints −0.07 +0.05 +0.01
(−0.28 – +0.15) (−0.17 – +0.27) (−0.21 – +0.23)
Number of tender joints +0.03 +0.04 +0.04
(−0.19 – +0.25) (−0.18 – +0.26) (−0.18 – +0.25)
VAS +0.13 +0.15 +0.17
(−0.09 – +0.34) (−0.07 – +0.36) (−0.05 – +0.37)
DAS28 −0.01 +0.02 +0.003
(−0.22 – +0.21) (−0.20 – +0.23) (−0.22 – +0.22)
CRP +0.02 +0.03 +0.01
(−0.20 – +0.24) (−0.20 – +0.25) (−0.21 – +0.23)
Eur J Clin Pharmacol (2012) 68:371–377 375apoptotic proteins. On the contrary, 17β-estradiol signifi-
cantly decreased the proapoptotic activity of LEF and
testosterone significantly increased apoptotic proteins in all
conditions [29].
Androgens exert anti-inflammatory activities in synovial
tissue, which contrasts with the proinflammatory activities
exerted by estrogens [30]. Serum testosterone levels are
inversely correlated with RA disease activity, and dehydroe-
piandrosterone sulfate (DHEAS) levels are inversely corre-
lated with both disease duration and clinical severity [31].
Adrenal and gonadal androgens, which exert anti-
inflammatory activities, are significantly decreased in in-
flamed tissues during active RA in both male and female
patients [30, 32]. Interestingly, increased aromatization of
androgens to estrogens has been demonstrated in cultured
synovial cells from RA patients [32, 33]. When androgens
are converted to their corresponding estrogens, the effects are
mediated by estrogen receptors. Our previous study indicated
an association between the response of women with RA to
LEFandESR1 gene polymorphisms. Results presented in the
study reported here suggest no correlation between CAG
repeat polymorphism in the androgen receptor gene and
response to LEF treatment of women with RA. This lack of
association may be due to increased conversion of androgens
to estrogens in RA, which exert proinflammatory activities
by estrogen receptors. Nevertheless, the role of androgens,
androgen receptors, and CAG repeat polymorphism in the
AR gene in the response to RA therapy requires further
investigations.
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